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SUMMARY
Understanding insulinlike growth factor1 (IGF1) biology is of particular importance because, apart from its
role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function,
development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF
binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To
determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we
used a genetargeting approach and generated two novel knockin mouse models of mutated IGF1, in which
the native Igf1 gene was replaced by DesIgf1 (KID mice) or R3Igf1 (KIR mice). The KID and KIR mutant
proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or ‘free IGF1’. We
found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum
growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly
reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased
body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the
spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The
KID and KIR models show unequivocally that IGF1complex formation with the IGFBPs is fundamental for
establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological
conditions.
INTRODUCTION
Insulinlike growth factor1 (IGF1) plays a pivotal role in fetal development, growth and tissue homeostasis.
Igf1null mice have marked growth retardation in utero and weigh 65% of normal weight at birth (Baker et
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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al., 1993; Liu et al., 1998). Postnatally, Igf1null mice do not undergo a peripubertal growth spurt and weigh
only 30% of adult wildtype animals. These mice are infertile, indicating that IGF1 plays an essential role in
the reproductive system. IGF1 receptor (Igf1r)null mice are 45% the weight of controls at birth and die
shortly thereafter owing to organ hypoplasia (Baker et al., 1993), identifying IGF1R as the main mediator of
IGF1 bioactivity. IGF1, together with insulin and growth hormone (GH), regulate glucose, lipid and protein
metabolism, and thereby regulate body composition. IGF1 is also involved in the regulation of innate and
acquired immunity, in wound healing and tissue repair, as well as in cognitive functions (for reviews, see
Yakar et al., 2005a; Yakar et al., 2005b; Yakar et al., 2002b).
IGFs are bound to IGFbinding proteins (IGFBPs), which modulate the actions of IGFs, facilitate their
storage in extracellular matrices and determine the net IGF bioactivity (Baxter, 2000; Mohan and Baylink,
2002). Previous studies were unable to determine whether IGF1 binding to IGFBPs at tissue sites is in fact
necessary to facilitate normal growth, development and/or metabolism. To date, six highaffinity IGFBPs
have been characterized (Baxter, 2000; Mohan and Baylink, 2002). Recent studies have demonstrated that
IGFBP levels vary depending on exercise (Wakai et al., 2009), surgery and pregnancy (Forbes and
Westwood, 2008), nutrition (Kaaks, 2004), and age (Frystyk, 2005), and that the levels of the various
IGFBPs are regulated by different hormones in serum and other biological fluids. Studies in mice lacking the
different IGFBPs show modest deficiencies in somatic growth (10–20% decreases in body weight), which
are mostly attributable to decreased IGF levels in serum and IGF stability in tissues (Ning et al., 2006). A
triple knockout of IGFBP3, IGFBP4 and IGFBP5, the main IGFBPs present in serum, results in an only
22% reduction in body weight, despite 65% decreases in serum IGF1 levels compared with wild type (Ning
et al., 2006). Similarly, gene inactivation of the acid labile subunit (ALS), which stabilizes the binary
complex of IGF1 and IGFBP3 or IGFBP5, results in an approximate 10–20% decrease in body weight
(Courtland et al., 2010; Yakar et al., 2009b). In our previous study we generated a tripleknockout mouse
with liver IGF1 deficiency (LID) and null alleles of the Igfals and Igfbp3 genes (LAB mice). Body weights
of LAB mice, followed from 3 to 16 weeks of age, were reduced by ∼20% as compared with control mice,
despite undetectable levels of IGF1 in serum (Yakar et al., 2009b). In that study, however, we also found
that genetic ablation of Igfbp3 (which produced only 40% reductions in serum IGF1) led to a ∼15% increase
in body weight (Yakar et al., 2009b). A study published by Stratikopoulos et al. (Stratikopoulos et al., 2008)
demonstrated that serum IGF1 contributes to determining approximately 30% of the adult body size,
providing additional support to the previous studies showing that marked reductions in serum IGF1 lead to
only a ∼20% decrease in body weight. Together, these studies support the notion that IGFBPs serve as
reservoirs that release the ligand, and control IGF action in serum and local microenvironments.
The solutionstructure of IGF1 has been solved by nuclear magnetic resonance (NMR) (Cooke et al., 1991;
Sato et al., 1993). In conjunction with IGF mutagenesis studies, the interaction of IGF1 with IGFBPs was
revealed and this led to the description of two IGF analogs that have a large reduction in affinity for the
IGFBPs but retain normal affinity for IGF1R: these analogs are R3IGF1 (Coolican et al., 1997; Flint et al.,
1994; McCusker et al., 1998) and Des13IGF1 (DesIGF1) (Ballard et al., 1987; Ballard et al., 1988; Ross
et al., 1989; Szabo et al., 1988). The R3IGF1 mutant has a Glu (E)toArg (R) substitution at position 3 of
the IGF1 peptide, and DesIGF1 has a threeaminoacid truncation at the Nterminus. Both mutants have
several times lower affinity for IGFBP3 than native IGF1 and show greatly reduced binding to all other
IGFBPs (Bayne et al., 1989; Gillespie et al., 1990; King et al., 1992; Lemmey et al., 1991).
The aim of the present study was to determine how unbound (bioavailable) IGF1 affects somatic growth and
skeletal acquisition, as well as tissue integrity and body composition. To that end we generated two mouse
models of knockin R3IGF1 (KIR) and DesIGF1 (KID), in which genes encoding mutant IGF1 replaced
the endogenous Igf1 gene and were expressed under the endogenous Igf1 promoter. These models offer
significant advantages over other models of an impaired IGF1 axis, allowing the study of the autocrine
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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effects of IGF1 independent of the IGFBPs. These mouse models represent an artificial situation in which
IGF1 is found in an unbound form and, thus, its posttranslational control is impaired and its bioactivity is
increased. In this study we describe the first characterization of KIR and KID mice during growth and
development.
RESULTS
Generation of mutant IGF1 mouse models using the knockin strategy

The generation of the two new mouse models of mutated IGF1 was based on extensive in vitro studies with
a variety of cell lines as well as on in vivo models whereby these mutants were injected or overexpressed.
The first mutant has an amino acid substitution of E to R at position 3 and was therefore named knockin R
(KIR). The second mutant has a deletion of the first three amino acids of IGF1 (DesIGF1) and was
therefore named knockin D (KID). Both IGF1 mutant peptides have similar affinity for IGF1R as does the
wildtype IGF1 peptide. However, these two mutants have several times lower affinity for IGFBP3 than
natural IGF1 and have greatly reduced binding to other IGFBPs. KIR and KID mutations were introduced
separately into the mouse genome by a knockin technique (Fig. 1); therefore, the mutated IGF1 molecule is
expressed under its natural promoter (and the regulation of the Igf1 promoter is not affected). The two target
constructs were injected into mouse embryonic stem (ES) cells (C57BL/6J strain). The targeting constructs
included a negative selection marker [herpes simplex virus (HSV) thymidine kinase (TK)] and a positive
selection marker, i.e. neomycin (Neo) resistance. When genetic recombination occurred in the correct genetic
loci, the TK marker was removed and only the neo cassette and the introduced mutated Igf1 were
incorporated into the genome. The neomycin cassette was removed by crossing the founder mouse lines with
EIIaCre transgenic mice, in which Crerecombinase is expressed at the twoto fourcell stage.
KID and KIR mice show impaired regulation of the GHIGF1 axis, leading to decreased ternary
complex formation in serum

Serum IGF1 levels in KID and KIR mice were assessed by commercially available radioimmunoassay (RIA)
kits using polyclonal antibody. Using this assay we found marked reductions in serum IGF1 levels at 4, 8
and 16 weeks of age (Fig. 2A) in both KID and KIR mutants compared with controls. However, these
reductions might reflect reduced assay sensitivity. Therefore, we measured recombinant R3IGF1 and Des
IGF1 at known concentrations using the same RIA. We found that, at low concentrations (<150 ng/ml), the
precision of the kit was 70% for DesIGF1 but only 6% for R3IGF1 (supplementary material Fig. S1). We
therefore used a different RIA using the NIH polyclonal antibody (developed by Albert F. Parlow, National
Hormone and Peptide Program, CA), which recognizes the IGF1 mutants. We performed assays using Des
IGF1 for the standard curve and as a tracer, wildtype IGF1 for the standard curve and as a tracer, and a
combination of the two (detailed in supplementary material Fig. S1). In both assays we found that KID mice
have 60% reductions in total IGF1 levels in serum (Fig. 2B) compared with wild type, and KIR mice
showed even further reductions.
Next we looked at the bioactivity of free IGF1 in serum, using a cellbased IGF1 kinase receptor activation
(KIRA) bioassay (Chen et al., 2003), which determines the ability of serum to stimulate IGF1R in vitro.
Because serum is compared with a serial dilution of recombinant human IGF1 (rhIGF1), it is possible to
express the obtained results in mg/l. The KIRA results contrasted with those obtained by immunoassay,
because the KIRA bioassay yielded levels of bioactive IGF1 of similar magnitude in each of the three
groups, although some statistical differences were observed (Fig. 2C). Because sera obtained from KID mice
exhibited IGF1 bioactivity similar to that of control sera (by KIRA assay), we believe that the concentration
of DesIGF1 that we measured using the above RIA mostly represents the fraction of DesIGF1 mutant that
was bound to the IGFBPs (with lower affinity than wild type).
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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Serum levels of IGFBP3, the main binding protein of IGF1 in serum, decreased significantly (∼40%) in both
KID and KIR mice (Fig. 2D), suggesting decreased IGF1 binding to IGFBP3 and reduced IGFBP3IGF1
binary complex formation in serum. Lastly, we measured ALS levels in serum from control and mutant mice
by western blot assay and found no significant changes between the groups (Fig. 2E). Expression levels of
the Igf1, Igfals or Igfbp3 genes in the liver were assessed by realtime PCR and showed no differences
between the groups in both genders (Fig. 2E).
Consequently, by using 125IIGF1 (Yakar et al., 2009b), we examined the ability of serum from KID and
KIR mice to support the formation of ternary complexes. In this assay, the tracer 125IrhIGF1 is used to
displace the ‘cold’ (i.e. endogenous) IGF1 bound to IGFBPs in serum samples. This assay provides
qualitative information about the presence of all three components that are routinely seen in serum IGF1
binding ternary complexes (IGF1, a binding protein and ALS). Importantly, the percent binding seen in the
different fractions does not reflect an absolute concentration of any of the compounds in serum. As seen in
Fig. 3A, when rhIGF1 was used as a tracer, ternary complex formation (fractions 0–10) was largely reduced
in sera from KID and KIR mice, suggesting significant reductions in the levels of IGFBPs, as shown before (
Fig. 2D). However, IGF binary complexes (fractions 20–30) were present in KID and KIR sera. This
reflects the fact that DesIGF1 as well as R3IGF1 has lower affinity for the IGFBPs than does wildtype
IGF1, allowing more 125IrhIGF1 to displace the ‘cold’ mutant IGFs in serum. When 125IDesIGF1 was
used as tracer (Fig. 3B), we could not detect any binary or ternary complex formation in sera from control
mice (Fig. 3B). This reflects the fact that 125IDesIGF1 has a much lower affinity for the IGFBPs than does
wildtype IGF1 and therefore was not able to displace the ‘cold’ wildtype IGF1 in serum (from control
mice) (Fig. 3B). Using 125IDesIGF1 with serum from KID mice revealed the presence of binary and
ternary complexes (Fig. 3B), reflecting a greater displacement of ‘cold’ DesIGF1 (found in sera from KID
mice) with 125IDesIGF1.
Introduction of the KID and KIR mutation did not affect the Igf1 promoter region. Mutant Igf1 expression
levels in liver and muscle did not differ significantly from controls (data not shown). However, because
IGF1 levels in serum were reduced dramatically, we examined GH levels in serum (Fig. 2F). We found that,
at 8 weeks of age, both KID and KIR female mice showed an increase in the mean serum GH levels,
probably owing to reduced serum IGF1 levels and an impaired inhibitoryfeedback mechanism. However,
this observation must be taken cautiously because GH levels were measured only once per mouse.
Unbound (bioavailable) IGF1 increases body size and affects relative organ growth

Body weights of KID and KIR mice (Fig. 4A) were significantly increased from 4 to 16 weeks of age as
compared with controls in both genders. Likewise, both KID and KIR mice showed increased body length
at 4, 8 and 16 weeks of age (Fig. 4B). Body composition, assessed by NMR, revealed that, at 16 weeks of
age, relative lean mass (fatfree mass) in female and male KID and KIR mice increased as compared with
controls (Fig. 4C). By contrast, whereas, in control mice, body adiposity increased with age (Fig. 4D), in
KID and KIR mice relative body adiposity decreased in both genders. Likewise, the relative weights of
gonadal fat pads in KID and KIR mice were significantly lower than in controls (Table 1).
Unbound (bioavailable) IGF1 increases mammary gland complexity and stimulates uteral growth

We found that relative weights of livers, hearts and brains of KID and KIR mice did not differ significantly
from controls. By contrast, we found that the relative weights of kidney, pancreas and spleen increased in
KID and KIR mice at all ages studied (Table 1).
Transgenic mice with localized mammary gland overexpression of DeshumanIGF1 (DeshIGF1), created
using the whey acidic protein (WAP) promoter, demonstrate incomplete mammary involution and ductile
hypertrophy (Hadsell et al., 1996). To determine the impact of free IGF1 on mammary gland development in
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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KID and KIR mice, we analyzed female mammary glands at 4, 8 and 16 weeks of age. Interestingly,
mammary glands of KIR and KID mice showed a greater degree of complexity as compared with control
mice at all ages analyzed (Fig. 5). Glands from 16weekold KID and KIR mice demonstrated a 56.3% and
70.4% increased complexity over control mice, respectively (P<0.001).
In addition to the mammary ductal phenotype, KID and KIR mice possess uterine defects. Uterus from KID
and KIR mice were twofold larger than those of controls and appeared to be hyperplastic. Histological
examination revealed that, in KID and KIR mice, the epithelial height is increased and cell layers are
disorganized. The uterus stroma in KID and KIR mice appeared fibrotic, and the size of the myometrial layer
was increased (Fig. 6). Despite the aforementioned phenotype, KID and KIR female mice can support
embryonic development and litter size is not affected.
Unbound (bioavailable) IGF1 promotes linear growth and skeletal acquisition, and leads to robust
bones

To understand how free IGF1 affects cortical and trabecular bone architecture we dissected femurs from 16
weekold female mice and analyzed them using microcomputed tomography (microCT; Table 2). Our data
revealed that free IGF1 in KIR female mice promoted large increases in total crosssectional area (Tt.Ar.),
cortical bone area (Ct.Ar.), cortical thickness (Ct.Th.), polar moment of inertia (Jo), robustness
(Tt.Ar./length) and marrow area (Ma.Ar.). Cortical changes were less pronounced in KID mice and
consisted only of significant increases in Ct.Ar., Ct.Th. and Jo. Tissue mineral density (TMD) did not differ
significantly between control and KID or KIR mice. However, KIR mice had significantly reduced TMD as
compared with KID mice. To determine whether changes in morphology and composition altered
mechanical properties, femora from 16weekold female KID and KIR mice were subjected to fourpoint
bending. We found that both KID and KIR mice tended to have increased stiffness as compared with
controls, but these values did not reach statistical significance. However, maximum load was significantly
greater in KIR mice as compared with both KID and control mice.
Trabecular architecture, assessed at the distal femur, showed that the bone volume/total volume fraction
(BV/TV) increased markedly in KID mice as well as in KIR mice (borderline marked significance) when
compared with controls (Table 2). This increase resulted from a significant increase in trabecular number
(Tb.N.) in both KID and KIR mice, and a consequent decrease in trabecular spacing (Tb.Sp.) in KID and
KIR (borderline significant) mice. There were no statistically significant differences in trabecular thickness
(Tb.Th.) or TMD when comparing strains.
In agreement with the microCT data, we found that the bone formation marker osteocalcin was elevated
significantly in KIR mice, whereas KID mice did not differ from controls (Table 2).
DISCUSSION
Using a genetargeting approach we generated two novel knockin IGF1 mutant models, in which the native
Igf1 gene was replaced by DesIGF1 (KID) or R3IGF1 (KIR). We demonstrated that IGF analogs are more
potent in increasing somatic growth than native IGF1 in vivo, and this is tissue specific and independent of
serum IGF1 levels. Although these are two artificial mouse models, studying their phenotype enhanced our
understanding of the biology of IGF1 in tissues.
Reductions in serum IGF1 levels in KID and KIR mice are consistent with data showing reduced stability of
those analogs in serum (Ballard et al., 1991; Bastian et al., 1993; Francis et al., 1990), in particular with the
observation that recombinant DesIGF1 injected into nude mice was rapidly cleared from serum and
distributed to tissues (Ballard et al., 1991; Sun et al., 1997). It is important to note that serum IGF1 levels in
KID and KIR mice were similar to those reported for LID, IGFBP3 knockout (IGFBP3KO) or ALS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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knockout (ALSKO) mice (Yakar et al., 2009b). Reduced serum IGF1 levels in KID and KIR mice
correlated with reduced serum IGFBP3 levels, probably owing to reduced IGF1IGFBP3 complex formation
and rapid degradation of the latter. Serum IGFBP3 concentrations in KID and KIR mice were similar to
those found in LID mice with low levels of IGF1 and normal levels of the ALS protein (Yakar et al.,
2009b). By contrast, ALSKO mice, which also have decreased serum IGF1 levels, exhibit markedly reduced
serum IGFBP3 (Yakar et al., 2009b), supporting the notion that binding of ALS to IGFBP3 (and not IGF1
to IGFBP3) is an important factor in determining IGFBP3 stability in serum. In humans, total ablation of the
IGF1 gene (reported in one patient) did not alter serum IGFBP3 (Woods et al., 1996). However, in humans,
IGFBP3 also binds IGF2, which stabilizes it in serum, whereas, in the mouse, IGF2 is not detectable in
serum postnatally. Because Igfals gene expression in KID and KIR mice is intact, we did not expect a
dramatic decrease in IGFBP3 levels in serum. In the present study, we also found that the ability of the two
IGF1 mutants to form ternary complexes of IGF1IGFBP3ALS in serum was dramatically reduced,
resembling the phenotype of ALSKO mice (Yakar et al., 2009b). However, unlike ALSKO mice, which
exhibited mild growth retardation, KID and KIR mice showed increased growth, implying that IGF1
bioactivity in tissues was increased. It is important to note that, despite reductions in total IGF1 levels in the
serum of KID and KIR mice, we did not find changes in free IGF1 levels in the serum between the groups.
Thus, our studies refer to the role of free IGF1 in tissues; the biological significance of free IGF1 in serum is
not yet resolved.
Similar to our previous observations with LID mice (Yakar et al., 2001; Yakar et al., 2004), the decreases in
serum IGF1 in KID and KIR mice resulted in increased serum GH levels. These elevations result from a
feedback loop between serum IGF1 and the pituitary. However, despite extensive experimentations trying to
understand the nature of this loop, it is yet unknown what form of IGF1 (ternary complex, binary complex or
free) feeds back to the pituitary. In ALSKO or IGFBP3KO mice, despite decreases in serum IGF1 levels,
we could not detect increases in serum GH in both male and female mice from 4 to 16 weeks of age.
Similarly, IGFALSdeficient humans, in which serum levels of IGF1 reduce dramatically, do not always
show elevations in serum GH (Domene et al., 2009). Indeed, these data from the mouse models and the
human counterparts raise new questions regarding the IGFGH feedback regulation. Overall, we cannot
exclude the possibility that the increases in GH levels together with increased IGF1 bioactivity of the analogs
are in fact responsible for increased growth.
Unlike LID mice, which had a body size similar to controls up to ∼10 weeks of age and then started to fall
off the curve, KID and KIR mice showed increased body growth even up to 16 weeks. In LID mice we did
not detect any increases in tissue IGF1 in response to GH elevations and, because body size did not differ
from controls, we speculated that tissue IGF1 bioactivity was comparable. By contrast, although tissue Igf1
gene expression did not differ between controls and KID or KIR mice, both mutants showed increased body
size, again suggesting increased IGF1 bioactivity in tissues.
Strikingly, assessments of body composition by NMR showed increased lean (fatfree) mass in KID and
KIR mice. However, this increase in lean mass was not reflected in the weight of the quadriceps (Table 1),
which in fact exhibited decreased relative weight as compared with controls. The decrease in muscle weight
in KID and KIR mice might result from muscletypespecific effects of the IGF1 analogs, or uncoupling
between muscle mass gain and body weight gain in KID and KIR mice. Those possibilities will have to be
evaluated in future studies. Also, examinations of the KID and KIR models together with models of
sarcopenia or muscle cachexia will give us a better insight into the role of bioactive IGF1 in maintaining
muscle integrity under extreme conditions.
Fat content, by contrast, was decreased in both KID and KIR mice. It is conceivable that these alterations
resulted from increased IGF1 bioavailability in adipose tissue. These observations are consistent with
previous data in humans showing that IGF1 promotes increases in fatfree mass (Butterfield et al., 1997;
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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Crist and Hill, 1990; Thompson et al., 1995) and decreases in fat mass (Thompson et al., 1995).
Alternatively, it is possible that elevations in serum GH levels resulted in increased lipolysis and subsequent
decreases in fat mass.
Not all organs responded equally to the genetic modifications. We found that spleen, kidney and uterus
relative weights increased in KID and KIR mice, whereas relative weights of liver, pancreas, lungs and brain
did not differ from controls. These observations are consistent with previous findings in IGF1 transgenic
mice, in which only selective organs responded to the high levels of IGF1 (Mathews et al., 1988). Also in
agreement with previous publications, we found that free IGF1 enhanced mammary gland complexity and
increased the uterine size in both KID and KIR mice. Together, these results suggest increased sensitivity of
the female reproductive organs to IGF1 and this finding might be applicable to increased tumor incidence
later in life.
Perhaps the most surprising data came from skeletal characterization of the KID and KIR mice. We found
that free IGF1 in KIR mice promoted increases in all morphological bone traits, resulting in more robust,
stronger bones when compared with controls. Interestingly, we found that KIR mice had a more profound
phenotype than KID mice, the latter of which only showing enhancement of Ct.Ar. and thus the
mathematically related traits Ct.Th. and Jo. This suggests that the KIR mutant protein is more potent than the
KID mutant at skeletal sites. Specifically, the KIR mutant seems to enhance both periosteal apposition and
endosteal resorption, as evidenced by significant increases in Tt.Ar. and Ma.Ar. Previous studies with animal
models of serum IGF1 deficiency [LID (Yakar et al., 2009a), ALSKO (Courtland et al., 2010) or double
mutants LID/ALSKO mice (Yakar et al., 2006)] showed that reductions in serum IGF1 levels were
associated with decreased bone accrual and with slender, mechanically inferior bones. By contrast,
IGFBP3KO mice, which also show decreases in serum IGF1, exhibited a more robust bone phenotype when
compared with controls (Yakar et al., 2009b). This was attributed in part to the growthinhibitory effect of
IGFBP3: this inhibition was released in Igfbp3null mice, leaving free IGF1 to interact with its receptor. Our
current study is in line with the data obtained from the IGFBP3KO mice, suggesting that the poor binding of
the KID and KIR mutant IGFs to IGFBPs, not only in serum but, most importantly, at tissue sites, enhanced
IGF1 action.
IGF and its binding proteins (IGFBPs) continue to attract attention as potential therapeutics for a wide range
of diseaserelated complications and cancer. Understanding IGF1 biology is of particular importance, even
apart from its role in mediating growth, because it plays key roles in cellular transformation, organ
regeneration, immune function, aging, sarcopenia, cachexia and skeletal growth. The KID and KIR models
show unequivocally that IGF1complex formation with the IGFBPs is fundamental for establishing normal
body and organ size. These models, although artificial, represent useful tools to study the contribution of free
IGF1 to physiological growth and pathological states.
METHODS
Animals

All mice were on the C57BL/6 genetic background. Mice were housed four per cage in a clean mouse
facility and fed a standard mouse chow (Purina Laboratory Chow 5001; Purina Mills) and water ad libitum,
and kept on a 12hour lightdark cycle. Animal care and maintenance were provided through the Mount
Sinai School of Medicine AAALAC Accredited Animal Facility. All procedures were approved by the
Animal Care and Use Committee of Mount Sinai School of Medicine.
Constructs used for the generation of knockin mice

The 5.8kb mouse Igf1 gene fragments containing point mutation L3R or with the first three amino acids
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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deleted (DES) at exon 2 (Fig. 1A) were generated by three rounds of special PCR with the Phusion DNA
polymerase (Finnzymes) under the following conditions: 98°C for 2 minutes, 98°C for 10 seconds, 59°C for
30 seconds, 72°C for 150 seconds with 35 cycles then a following 10 minutes at 72°C and storage at 4°C.
The mutations were confirmed by DNA sequencing. Fragments were cloned into pCR Blunt IITOPO
vector (Invitrogen). A conditional genetargeting vector was constructed from this 5.8kb Igf1 gene by a
novel recombineering approach adapted from Liu et al. (Liu et al., 2003). Briefly, the 5.8kb fragment from
the above pCR Blunt IITOPO construct was cut out by NotI and SpeI, then ligated to PL253 vector
containing the thymidine kinase cassette. This subcloned genomic region was then modified in a targeting
approach using the neo cassettes from the PL452 vector. A floxed neo cassette from PL452 was inserted to
Igf1 intron 1. The genetargeting vector was tested for functionality by transformation into arabinoseinduced
SW106 cells and the neo cassette removed using arabinoseinduced Creexpressing SW106 cells, which
leave behind only a single loxP site in Igf1 intron 1. The conditional targeting vector was then linearized by
NotI digestion and electroporated into B6/129 F1 hybrid ES (V6.5) cells using standard procedures. G418
(200 μg/ml)resistant clones were analyzed by Southern blot hybridization, using external 5′ probes (
Fig. 1A,B). Targeted clones were confirmed by DNA sequencing (Fig. 1C). The targeted clones harboring
the loxPflanked neo cassette were injected into C57BL/6 blastocysts using standard procedures. After
conformation of germline transmission, mice were crossed to EIIacre transgenic mice (Jackson Laboratories
#003724) to remove the neo cassette. The knockin lines were backcrossed to C57BL/6J (Jackson
Laboratories #000664) for seven generations and maintained by intercrossing homozygous knockin mice.
Determination of serum hormones

Mice were bled through the mandibular vein and serum samples were collected at the indicated ages. Serum
IGF1 (American Laboratory Products Company, Salem, NH) and, with RIA developed by Albert F. Parlow
(National Hormone and Peptide Program), osteocalcin (American Laboratory Products Company) and
insulin (Millipore, Temecula, CA) levels were determined using commercial RIAs as previously described
(Pennisi et al., 2006; Yakar et al., 2002a; Yakar et al., 2004). Plasma IGFBP3 levels and GH levels (both
Millipore) were determined using ELISA assays.
Determination of serum IGF1 ternary complex formation

The protocol was adopted from Baxter and Martin (Baxter and Martin, 1989). 100 μl serum samples were
incubated overnight at 22°C with I125IGF1 (at a final concentration of 10 ng/ml), then crosslinked with
disuccinimidyl suberate as reported before (Domene et al., 2004). Complexes were separated using HiPrep
16/60 Sephacryl S200HR columns and 1 ml fractions were collected and counted.
Determination of serum bioactive IGF1

This assay was performed as previously described (Chen et al., 2003). In brief, serum samples (diluted 1:20)
were incubated with transfected cells for 15 minutes at 37°C. Next, samples were aspirated, cells lysed and
the crude cell lysates assayed for levels of phosphorylated (i.e. activated) IGF1Rs by a specific TRIFMA as
previously detailed (Chen et al., 2003). The serum signals were compared with those of a serial dilution of
rhIGF1, calibrated against the rhIGF1 WHO International Standard preparation 02/254 (obtained from
NIBSC, Hertfordshire, UK). The KIRA is relatively specific for IGF1 – IGF2 and insulin crossreactivity
equals 12% and <1%, respectively – and it is also precise [within and between assay coefficient variances
(CVs) average 7% and 15%, respectively].
Determination of serum ALS

Sera were diluted 1:4 with saline and subsequently separated on a 4–12% acrylamide gel and transferred to
nitrocellulose. Membrane was blocked with LICOR block solution (Lincoln, NE) and incubated overnight
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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at 4°C with a goat antiALS antibody (R&D Systems, Minneapolis, MN). Following washing, the
membrane was incubated with IRDye 800CWdonkey antigoat antibody (LICOR). Bound antibodies were
detected by LICOR Odyssey infrared imaging system.
Determination of body composition

Body adiposity was measured using a Bruker minispec NMR analyzer mq 10 in nonanesthetized mice
(Bruker Optics, Woodlands, TX).
MicroCT

The bone samples were scanned using a highresolution SkyScan microCT system. Images were acquired
using a 10 MP digital detector, 10 W power energy (100 KV and 100 μA) and a 0.5mm aluminum filter. X
ray projections are generated from the sample each 0.3 degrees, obtaining 680 consecutive views with a 6.7
μm image pixel size. Five exposures by projection (1767millisecond exposure time) were used to produce
highcontrast lownoise images. A system alignment procedure and flat field calibration were performed
prior the scanning sequence.
Trabecular and cortical regions were defined as positions along the long axis of the femur relative to the
growth plate reference. The cortical region of interest was selected as ±1.5 mm in length from the mid
diaphysis of the bone. The trabecular metaphyseal region was selected as 3 mm in length from the distal
growth plate towards the diaphysis.
A modified backprojection reconstruction algorithm (NRecon, V. 1.6.1.2) included in the SkyScan
acquisition system was used to generate crosssection images from the planar Xray projections. Throughout
the reconstruction procedure, images were optimized using a standard postalignment compensation
algorithm, eliminating misalignment artifacts. Images were also treated using a smoothing filter (kernel=1)
with a Gaussian window, ring artifact correction (=15) and beam hardening correction (49%). All the
reconstruction parameters were applied identically to all bone scans and to the calibration scan of the bone
mineral density (BMD) rods, with the exception of the postalignment compensation.
Mechanical testing

Mouse femora from 16weekold control, KID and KIR mice were tested to failure by fourpoint bending
using a servohydraulic materials testing system (Instron, Canton, MA). This test was used to measure whole
bone stiffness and maximum load (strength). Femora were placed with the anterior surface down on two
lower supports. The two lower and two upper supports were set apart by 6.35 and 2.2 mm, respectively.
Loading was centered over the midshaft, at a displacement of 0.05 mm/second until failure. All mechanical
properties were calculated from the loaddisplacement curves, as described previously (Jepsen et al., 2007).
Histology

Tissues were dissected from euthanized mice, fixed in 10% buffered formalin for 24–48 hours and
embedded in paraffin blocks. 5μm sections were cut and stained with hematoxylin and eosin according to
standard procedures.
TRANSLATIONAL IMPACT
Clinical issue

An imbalance in the tightly regulated levels of insulinlike growth factor1 (IGF1) has been associated
with various pathological conditions, including type 2 diabetes, cachexia, chronic inflammatory
conditions (such as inflammatory bowel disease), obesity, and ageassociated decline in mental and
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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physical competence. In addition, it has long been thought that supplementation with free IGF1 (e.g.
DesIGF1) can enhance athletic performance. Owing to its central role in the regulation of cell survival,
cell cycle progression and cell differentiation, an imbalance in the expression of IGF1 or its receptor,
IGF1R, could lead to uncontrolled cell division and ultimately to malignant transformation. Indeed,
increased levels of IGF1 and IGF1R have been documented in multiple types of human malignancy.
Increased levels of IGF1 have also been reported in acromegaly (involving excess production of growth
hormone) and are associated with organomegaly (enlargement of organs), osteoarthritis and colonic
polyps. A better understanding of the role of IGF1 and IGF1R in normal and pathological conditions
would increase our understanding of the wide range of diseases in which their expression is altered.
Results

In this study, the authors use a genetargeting approach to generate two novel knockin mouse models
(referred to as KID and KIR strains) that allow them to assess the effect of free (unbound) IGF1 on
growth and development. Both the KID and KIR mouse strains carry a different form of mouse IGF1
with a reduced ability to bind IGFbinding proteins (IGFBPs), leading to reduced concentrations of IGF1
in serum. Both strains of mice exhibit increased somatic growth, as indicated by increased body weight
and increased body and bone lengths. In addition, the mice exhibit selective organomegaly of the spleen,
kidney and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The
phenotype of these two mouse strains suggests that increased IGF1 activity in tissues leads to
uncontrolled growth.
Implications and future directions

DesIGF1 is currently available for personal use and is sold to athletes for improvement of muscle
anabolism. However, the longterm effects of taking supplements such as DesIGF1 are not yet known.
The KID and KIR mouse models characterized here will help to better understand the longterm effects
of IGF1 supplementation as well as the potential impact of free IGF1 on neoplasia and health or lifespan.
These initial studies suggest that DesIGF1 might be useful in the treatment of human disorders
associated with an imbalance in IGF1 levels, such as sarcopenia or muscle cachexia. Furthermore, the
KID and KIR mouse models will enable future investigations of mechanisms of learning and memory
that are controlled by IGF1 in vivo.
Gene expression studies

Total RNA from livers and bone marrow cultures was extracted (TRIzol, Invitrogen, Carlsbad, CA) and
RNA integrity verified (BioanalyzerBio Sizing 2100, Version A.02.12 SI292, Agilent Technologies). RNA
samples (1 mg) were reversetranscribed using oligo(dT) primers (Invitrogen) and quantitative realtime PCR
performed following the manufacturer’s instructions using the QuantiTect SYBR Green PCR kit (Qiagen,
Valencia, CA) in ABI PRISM 7900HT sequence detection systems (Applied Biosystems, Foster City, CA).
Each transcript in each sample was assayed three times and the foldchange ratios between experimental and
control samples were calculated relative to βactin.
Statistical analysis

All differences in mean serum hormones, organ weights, body composition and growth among the different
groups were assessed by ANOVA. Values are presented as mean ± s.e.m.; P<0.05 was considered
statistically significant.
All bone traits, body weight, body composition, serum hormones and microCT measurements are presented
as means ± s.e.m. Oneway analysis of variance (ANOVA) was used to test for differences among groups at
each age (Statview software version 5.0, SAS Institute). If ANOVA revealed significant effects, the means
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable
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were compared by Fisher’s test, considering P<0.05 as significant.
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Knockin strategy. (A) Schematic representation of the targeting construct, in which the two mutations in exon 2 were
introduced, adjacent to a neo cassette flanked by two loxP sites (used for selection). The neo cassette was subsequently
removed using the Cre transgene. (B) Southern blot analysis was used to identify embryonic cell mutant clones (knockin;
KI). Above the blot we present a schematic of the mutated peptides. (C) Sequence analysis confirmed the mutations. WT,
wild type.
Fig. 2.
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KID and KIR mice show significant decreases in serum IGF1 and IGFBP3 levels, and increases GH levels. (A)
Serum IGF1 levels determined at 4, 8 and 16 weeks of age by RIA (ALPCO) were significantly lower in KID and KIR mice
as compared with controls (n=5 per age and genetic group). (B) Serum IGF1 levels determined at 8 weeks of age by RIA
(NIH) were significantly lower in KID and KIR mice as compared with controls. (C) Serum free IGF1 levels determined by
KIRA. (D) Serum IGFBP3 levels from 8weekold female KID and KIR mice were decreased compared with controls
(n=5–12 per genetic group). (E) Serum ALS levels as measured by western blot (n=5 in each group) and expression levels
of Igf1, Als, Igfbp3 and Ghr genes in livers from control, KID and KIR mice at 8 weeks of age. (F) Serum GH levels from 8
weekold female KID and KIR mice were increased compared with controls (n=5–12 per genetic group). Data presented as
mean ± s.e.m.; P<0.05 was considered statistically significant (* denotes significance between control and KID; # denotes
significance between control and KIR).
Fig. 3.
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Profiles of ternary complex formation in sera from control, KID and KIR mice. Each profile represents six mice. (A,B)
Complex formation using I125rhIGF1 (A) or I125DesIGF1 (B) as a tracer. CPMX10, counts per minute × 10; WT,
control (wild type).
Fig. 4.
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Free IGF1 increases body weight, body length and lean mass and decreases body adiposity in both male and female
mice. (A) Body weight was followed weekly. Both KID and KIR mice show a significant increase in body weight as
compared with controls (n=10 to 20 per age and genetic group). (B) Body length (nose to anus), measured at 16 weeks of
age, increased significantly in KID and KIR mice (n=10 per age and genetic group). (C,D) Body composition assessed by
NMR revealed a significant increase in lean (fatfree) mass in both KID and KIR mice (D), whereas fat mass significantly
decreased (C) (n=10 per age and genetic group). xaxis represents weeks. Data are presented as mean ± s.e.m.; P<0.05 was
considered statistically significant (* denotes significance between control and KID mice; # denotes significance between
control and KIR mice). WW, control (wildtype) mice.
Table 1.

Relative weights of organs dissected from 16weekold female mice
Table 2.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180229/?report=printable

18/21

10/26/2015

Unbound (bioavailable) IGF1 enhances somatic growth

Skeletal traits of femurs isolated from 16weekold female mice
Fig. 5.
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Mammary gland morphology in control, KID and KIR female mice. (A) Mammary gland complexity was measured in
female control, KID and KIR mice at 4, 8 and 16 weeks of age (for all groups, n=3–10 at 4 weeks of age, n=10–16 at 8
weeks of age and n=12–20 at 16 weeks of age). Differences between groups were measured by onefactor ANOVA. Values
are presented as the mean ± s.e.m. P<0.05 was considered statistically significant. WW, control (wildtype) mice. (B)
Complexity is a measure of the extent of ductal branching and was quantified using MicroSuite Basic imaging software to
determine the number of intersecting branches along a line drawn midway between the leading edge of the ducts and each
side of the lymph node. Broken line indicates the central line across the mammary fat pad. (C) Representative images of
inguinal mammary gland whole mounts dissected from 16weekold female control, KID and KIR mice. The glands were
spread on a microscope slide and fixed in Carnoy’s solution (60% absolute ethanol, 30% chloroform, 10% glacial acetic
acid) for 2–4 hours. The fat pads were then hydrated in graded ethanol solutions and placed in Carmine Alum stain
overnight. They were then dehydrated in graded ethanol solutions and finally placed in xylene prior to mounting with
MountQuick mounting medium.
Fig. 6.
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Uterus histology in control, KID and KIR female mice. Images of uterus dissected from 16weekold virgin female
control, KID and KIR mice. (Top row) The myometrium height is indicated on sections stained with H&E. (Middle row)
The uterine epithelial cell layer in KID and KIR mice is disorganized and the stroma layer (bottom row) exhibits fibrosis.
Scale bars: 2 mm (top row); 500 μm (middle row); 200 μm (bottom row).
Articles from Disease Models & Mechanisms are provided here courtesy of Company of Biologists
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